Latest news with #Olympus
Yahoo
29-05-2025
- Business
- Yahoo
Olympus Announces Launch of New Endoscope Drying Cabinet
ScopeLocker Air Offers Flexible Size and Air Options for Space-Conscious Facilities; Olympus to Highlight New Drying Cabinet at Annual SGNA Conference CENTER VALLEY, Pa., May 29, 2025 /PRNewswire/ -- Olympus Corp., a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today the launch of the ScopeLocker Air endoscope drying cabinet, offering a new drying option for healthcare facilities. Drying endoscope channels is a critical component of reprocessing. The ScopeLocker Air endoscope drying cabinet, manufactured by Capsa Healthcare and distributed by Olympus Corp., helps facilitate the drying process and is designed to meet society guidelines for endoscope drying and storage. With this new model, multiple size and material options are available to meet facility needs. The 41-inch- wide ScopeLocker Air drying cabinet can accommodate up to 18 endoscopes, while the 22-inch-wide cabinet, which is ideal for smaller facilities such as ambulatory surgery centers, can accommodate up to eight endoscopes. Powder-coated steel and stainless-steel options are available for all models. Providing continuous airflow through channels and around the outside of the endoscope, the ScopeLocker Air drying cabinet aids in the reprocessing cycle by providing an air source option that is built into the cabinet. The ScopeLocker Air drying cabinet improves the ScopeLocker with HEPA storage cabinets healthcare facilities have been using for years by adding air manifolds, autoclavable connectors and HEPA-filtered air pumps into the top of the cabinet for additional space efficiency. Facilities can also choose to use their own air source. Other features of the ScopeLocker Air include: Rotating scope holders for easy access to the second row of endoscopes An air manifold designed to easily connect up to 18 scopes A padded lower back wall designed to protect the distal tip of an endoscope with optional side padding available A center separator scope rack designed to keep scopes from touching during storage Optional electronic keyless entry for all cabinet options Optional LED lighting. Olympus will highlight the ScopeLocker Air during the annual Society of Gastroenterology Nurses and Associates (SGNA) conference June 1-3 in Pittsburgh. Olympus will also offer continuing education sessions focusing on reprocessing. Sessions include: Training and Education in Medical Device Reprocessing: Bridging Knowledge and Safety Beyond the Scope: Preventing Cross-contamination from Reprocessing Accessories. "Patient safety is at the center of all we do, and this newest drying cabinet is part of a larger infection prevention portfolio and strategy to help facilities address their reprocessing needs," said Patrick Romano, Vice President, GI Business Unit Leader, Olympus Corporation of the Americas. "We are excited to highlight ScopeLocker Air and offer continuing education sessions on reprocessing for the dedicated professionals attending the annual SGNA meeting. Olympus remains committed to providing the solutions and education to help healthcare professionals offer the best care possible to their patients." For more information about Olympus' GI and infection prevention offerings, visit the Olympus booth, #620, during SGNA or visit the GI page to view the full portfolio or the infection prevention page for more infection prevention resources. About OlympusAt Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. Olympus Corporation of the Americas, a wholly owned subsidiary of Olympus Corporation, is headquartered in Center Valley, Pennsylvania, USA, and employs more than 4,500 employees throughout locations in North and South America. For more information, visit View original content to download multimedia: SOURCE Olympus Corporation of the Americas
Yahoo
27-05-2025
- Business
- Yahoo
Olympus Announces FDA Clearance of Its Most Advanced Imaging Endoscopes
EDOF™ Technology Provides a Continuously Sharp Image with Minimal Focal Adjustment as Part of the EVIS X1™ Endoscopy System CENTER VALLEY, Pa., May 27, 2025 /PRNewswire/ -- Olympus, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today FDA 510(k) clearance of its EZ1500 series endoscopes featuring Extended Depth of Field (EDOF™) technology. EDOF™ endoscopes – the GIF-EZ1500 gastroscope and the CF-EZ1500DL/I colonoscope – represent Olympus' most advanced imaging and latest innovation as part of the EVIS X1™ endoscopy system. By allowing physicians to obtain sharp images, EDOF technology allows an entire lesion to be kept in focus and may aid in detection as endoscopists inspect the mucosal lining of the GI tract. EDOF technology creates an image in total focus by using two prisms to split light entering the endoscope lens into two separate beams with near- and far-focused images. Those beams are then projected simultaneously onto an image sensor, combining them into one image with a wide depth of field.1 Compared to the previous generation of Olympus® scopes, this technology provides improved visibility and less blurring. The EZ1500 series EDOF scopes allow for closer distance in normal mode compared to the CF-HQ190L/I – 3mm vs. 5mm – without blurring, limiting the need to switch from normal to near mode. The GIF-EZ1500 gastroscope and the CF-EZ1500DL/I colonoscope also feature a lightweight ErgoGrip™ control section and compatibility with Texture and Color Enhancement Imaging (TXI™), Red Dichromatic Imaging (RDI™) and Narrow Band Imaging™ (NBI™) technologies when connected to the EVIS X1 CV-1500 video system center. The ErgoGrip™ control section of EVIS X1 endoscopes is 10% lighter than the 190 series scope control section and features a rounded handle and easy-to-reach angulation control knobs and switches to accommodate users with small hands and support scope maneuverability.2 "As a leading global MedTech company, Olympus remains committed to providing advanced options to help physicians offer their patients the best care possible," said Kurt Heine, Senior Vice President and General Manager for Gastrointestinal Solutions at Olympus Corporation. "Our goal is to elevate the standard of endoscopy, and Extended Depth of Field (EDOF) technology represents Olympus' most advanced scope technology to help physicians drive the best clinical outcomes for advancing gastrointestinal procedures." The EVIS X1™ endoscopy system revolutionizes the way gastrointestinal disorders are detected, characterized and treated with innovative, easy-to-use diagnostic and therapeutic technologies and improved scope handling. The EVIS X1 endoscopy system provides a high level of patient care for every endoscopist, in every procedure, every day. In addition to the newest EDOF technology, features of the EVIS X1 endoscopy system include: TXI™ technology, which is designed to increase the visibility of lesions and polyps by enhancing image color and texture.3 RDI™ technology, which is designed to enhance the visibility of deep blood vessels and bleeding points.3 NBI™ technology, which enhances visual observation of mucosal and vascular patterns by utilizing specific blue and green wavelengths absorbed by hemoglobin.3 Brightness Adjustment Imaging with Maintenance of Contrast (BAI-MAC™) technology, which is designed to correct the brightness levels in dark areas of the endoscopic image, while maintaining the brightness of lighter areas, to increase the total distance view.4 TXI, RDI, BAI-MAC and NBI technologies are not intended to replace histopathological sampling as a means of diagnosis. These are adjunctive tools for endoscopic examination that can be used to supplement Olympus® white light imaging. Visit the EDOF product page and the EVIS X1 product page or the gastroenterology page for more information about the entire Olympus GI portfolio. About OlympusAt Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. Olympus Corporation of the Americas, a wholly owned subsidiary of Olympus Corporation, is headquartered in Center Valley, Pennsylvania, USA, and employs more than 4,500 employees throughout locations in North and South America. For more information, visit 1 Data on file with Olympus (DC00493386, DC00433276, DC00510434 and DC00567392)2 Data on file with Olympus (DC00600786, DC00482729, DC00031984, DC00482747, DC00779274, DC00031984, DC00600794, DC00481878, DC00031984, DC00841888 and DC00833645)3 Data on file with Olympus (DC00489968)4 Data on file with Olympus (DC00436067) View original content to download multimedia: SOURCE Olympus Corporation of the Americas Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Nikkei Asia
23-05-2025
- Business
- Nikkei Asia
Japanese medical device makers stand up to Trump tariff pressure
TOKYO -- Japanese medical device manufacturers are showing resilience to U.S. tariff threats thanks to their specialized manufacturing expertise, focus on niche markets and pricing power. Leading manufacturers such as Terumo and Olympus, both based in Tokyo, are expected to pass on at least some of the tariff costs to U.S. customers.
Malaysian Reserve
22-05-2025
- Health
- Malaysian Reserve
AMA Establishes CPT Codes for Minimally Invasive ESD Procedure
CENTER VALLEY, Pa., May 22, 2025 /PRNewswire/ — Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer, and more fulfilling, announced today the American Medical Association (AMA) Current Procedural Terminology (CPT®) Editorial Panel has published its Summary of Panel Actions and has agreed to establish two Category I CPT codes for the Endoscopic Submucosal Dissection (ESD) procedure: one code for the upper GI tract and one code for the lower GI tract.i The final code numbers, code descriptors and fee schedules will be published in November 2026, and the codes are anticipated to become effective January 1, 2027. The dedicated CPT codes for the ESD procedure will allow for more widespread clinical adoption of the procedure and remove barriers to patient access. This will be facilitated through a standardized and streamlined reimbursement process for health care providers and payers. 'We applaud the AMA's decision to establish these new CPT codes, which will help more patients and physicians access the ESD procedure for the minimally invasive treatment of pervasive GI diseases and disorders,' said Paul Skodny, Senior Director for Health Economics and Market Access at Olympus Corporation. 'This positive result is the culmination of much hard work and broad support for creating this reimbursement pathway.' ESD is a minimally invasive, organ-sparing endoscopic procedure used to diagnose and treat cancerous and pre-cancerous neoplasms of the gastrointestinal (GI) tract. Rather than surgically removing whole sections of the GI tract through incisions on the skin, physicians remove tumors through natural orifices, via an endoscope, in one piece. This technique enables accurate staging of these lesions by pathologists, leading to less recurrence rates than other endoscopic Without large incisions or having sections of organs removed, patients experience less pain, faster healing and may not suffer the potential consequences of segmental 'We are thrilled to reach this significant reimbursement milestone for the ESD procedure,' said Mike Callaghan, General Manager for EndoTherapy at Olympus Corporation. 'Olympus has been at the forefront of developing ESD solutions since the procedure was first pioneered by Japanese clinicians working collaboratively with Olympus. This decision by the AMA will facilitate broader adoption of this procedure in the U.S., and it will enhance patient care by providing more patients with access to an advanced and novel treatment option.' Visit the Olympus Americas ESD web page for more information about the ESD procedure: About OlympusAt Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. Olympus Corporation of the Americas, a wholly owned subsidiary of Olympus Corporation, is headquartered in Center Valley, Pennsylvania, USA, and employs more than 4,500 employees throughout locations in North and South America. For more information, visit i Summary of Panel Actions. Updated May 16, 2025. Accessed May 20, 2025. Fukami, N. Endoscopic Submucosal Dissection in the Esophagus: Indications, Techniques, and Outcomes, Gastrointestinal Endoscopy Clinics of North America. 2023;33(1);55-66. doi:10.1016/ Abdelfatah MM, Barakat M, Ahmad D, Ibrahim M, Ahmed Y, Kurdi Y, Grimm IS, Othman MO. Long-term outcomes of endoscopic submucosal dissection versus surgery in early gastric cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019;31(4):418-424. Doi:10.1097/MEG.0000000000001352. PMID: 30694909iv Qian M, Sheng Y, Wu M, Wang S, Zhang K. Comparison between Endoscopic Submucosal Dissection and Surgery in Patients with Early Gastric Cancer. Cancers. 2022; 14(15):3603.
Wales Online
20-05-2025
- Health
- Wales Online
Urologist urges men to watch for signs of BPH after Biden diagnosis
Urologist urges men to watch for signs of BPH after Biden diagnosis Most people are unaware of the symptoms, wouldn't discuss them with a doctor and don't know the treatment options A man discussing prostate health concerns Men have been warned to watch out for the signs of Benign Prostate Hyperplasia (BPH) after the diagnosis of former President of the USA Joe Biden. BPH is one of the most common prostate conditions in the UK, affecting nearly 80% of men over 75. BPH is a condition where the prostate enlarges, often pressing against the urethra and leading to urinary symptoms. Common symptoms include difficulty starting urination, a weak or inconsistent urine flow, frequent or urgent need to urinate, and occasional urinary incontinence. Although not life-threatening, BPH can have a significant impact on men's quality of life. A survey by Olympus found widespread misconceptions of BPH, with over three quarters of respondents unsure of what BPH is, and 86% unfamiliar with its symptoms. Many lack understanding of long-term treatment options. 63% were uncertain about the condition's connection to cancer with over a quarter falsely believing BPH is a type of prostate cancer. Richard Hindley, Consultant Urologist at OneWelbeck, the HCA Princess Grace Hospital and The Prostate Centre, said: 'While BPH is more common in men over 70, I regularly treat men as young as 40. Unfortunately, many delay seeking help, often out of embarrassment or misinformation. I encourage men to talk openly-whether with friends, family, and their doctor. If you've undergone treatment for BPH, please do bang the drum to help others. This condition is not only common but also highly manageable, so I urge men not to ignore the signs and speak to your GP." Article continues below Paul Sayer, founder of the Prost8 UK charity, said: 'Although we are primarily working to expand the use of minimally invasive treatments for prostate cancer, many of the patient enquiries we receive confuse the symptoms of BPH with potential prostate cancer. That is why we have expended our remit to help men to understand the condition better. We strive to direct men to the best treatment options available, such as iTind, which provides patients with a simple and highly effective way to relieve symptoms." Almost one fifth say they would not discuss their health symptoms with anyone. Former US president Joe Biden, 82, has been diagnosed with aggressive prostate cancer that has spread to his bones.
